| __timestamp | Opthea Limited | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2652041 | 5078000000 |
| Thursday, January 1, 2015 | 2361587 | 4717000000 |
| Friday, January 1, 2016 | 4472869 | 5096000000 |
| Sunday, January 1, 2017 | 5030957 | 4986000000 |
| Monday, January 1, 2018 | 4988941 | 4214000000 |
| Tuesday, January 1, 2019 | 5196412 | 3806000000 |
| Wednesday, January 1, 2020 | 6652774 | 3671000000 |
| Friday, January 1, 2021 | 18418247 | 3528000000 |
| Saturday, January 1, 2022 | 24827066 | 3445000000 |
| Sunday, January 1, 2023 | 41896408 | 3498000000 |
| Monday, January 1, 2024 | 15488619 | 3702000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, understanding operational efficiency is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Opthea Limited from 2014 to 2023.
Teva, a global leader, consistently reported SG&A expenses in the billions, peaking at approximately $5 billion in 2016. However, a downward trend is evident, with expenses dropping to around $3.5 billion by 2023, reflecting a strategic shift towards cost efficiency.
In contrast, Opthea, a smaller player, exhibited a dramatic rise in SG&A expenses, surging from $2.4 million in 2015 to over $41 million in 2023. This 1,600% increase underscores Opthea's aggressive expansion and investment in growth.
While Teva's expenses show a steady decline, Opthea's rapid increase highlights differing strategies in navigating the competitive pharmaceutical market.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Ionis Pharmaceuticals, Inc. vs Opthea Limited: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Opthea Limited and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? Opthea Limited or ImmunityBio, Inc.